Spruce Biosciences, Inc. (SPRB) company profile

Spruce Biosciences is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical needs. The company's portfolio features product candidates targeting serious conditions with established biological pathways, where approved treatments are unavailable or current options remain suboptimal. Its lead candidate, tralesinidase alfa enzyme replacement therapy, is an investigational fusion protein intended to restore alpha-N-acetylglucosaminidase enzyme activity in the central nervous system for patients with Mucopolysaccharidosis Type IIIB.

The company operates in the United States and plans international development across regions including North America, the European Union, the United Kingdom, Latin America, Turkey, and Asia. Spruce Biosciences conducts human clinical trials across multicenter and multinational sites to support its therapeutic pipeline. The business maintains its principal executive offices in South San Francisco, California.

Summary of the business section of Spruce Biosciences's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “SPRB.” The initial public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 8 employees, all of whom were full time, including 5 in research and development and 3 in general and administrative functions.”